Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Overview

Journal Lung Cancer (Auckl)

Publisher Dove Medical Press

Date 2023 Feb 10

PMID 36762267

Authors

Maria Concetta Nigro

Paola Valeria Marchese

Chiara Deiana

Chiara Casadio

Linda Galvani

Alessandro Di Federico

Andrea De Giglio

Affiliations

Soon will be listed here.

Abstract

Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, where advances have been remarkable. Tissue biopsy, required for tumor molecular testing, has significant limitations due to the difficulty of the biopsy site or the inadequacy of the histological specimen. In this context, liquid biopsy, consisting of the analysis of tumor-released materials circulating in body fluids, such as blood, is increasingly emerging as a valuable and non-invasive biomarker for detecting circulating tumor DNA (ctDNA) carrying molecular tumor signatures. In advanced/metastatic NSCLC, liquid biopsy drives target therapy by monitoring response to treatment and identifying eventual genomic mechanisms of resistance. In addition, recent data have shown a significant ability to detect minimal residual disease in early-stage lung cancer, underlying the potential application of liquid biopsy in the adjuvant setting, in early detection of recurrence, and also in the screening field. In this article, we present a review of the currently available data about the utility and application of liquid biopsy in lung cancer, with a particular focus on the approach to different techniques of analysis for liquid biopsy and a comparison with tissue samples as well as the potential practical uses in early and advanced/metastatic NSCLC.

Citing Articles

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report.

De Giglio A, Zacchini F, Venturi G, Di Federico A, Parisi C, DallOlio F J Liq Biopsy. 2025; 6:100161.

PMID: 40027319 PMC: 11863973. DOI: 10.1016/j.jlb.2024.100161.

Highly proliferating cancer cells function as novel prognostic biomarkers for lung adenocarcinoma with particular usefulness for stage IA risk stratification.

Xiong Y, Ma Y, Lei J, Zhu J, Xie N, Tian F BMC Cancer. 2025; 25(1):25.

PMID: 39773365 PMC: 11707901. DOI: 10.1186/s12885-024-13308-0.

A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement.

Manabe T, Kanayama M, Matsumiya H, Yoshimatsu K, Mori M, Nishizawa N Gen Thorac Cardiovasc Surg Cases. 2024; 3(1):44.

PMID: 39516998 PMC: 11533432. DOI: 10.1186/s44215-024-00169-z.

Detection and Characterization of Methylated Circulating Tumor DNA in Gastric Cancer.

Seo S, Youn S, Bae J, Lee S, Lee S Int J Mol Sci. 2024; 25(13).

PMID: 39000483 PMC: 11242052. DOI: 10.3390/ijms25137377.

Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches.

Prasanth B, Alkhowaiter S, Sawarkar G, Dharshini B, R Baskaran A Cureus. 2024; 15(12):e51090.

PMID: 38274938 PMC: 10808885. DOI: 10.7759/cureus.51090.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Nacchio M, Sgariglia R, Gristina V, Pisapia P, Pepe F, De Luca C . mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. J Thorac Dis. 2020; 12(7):3836-3843. PMC: 7399406. DOI: 10.21037/jtd.2020.01.19. View

Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G . Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-53. PMC: 4224589. DOI: 10.1097/JTO.0000000000000263. View

Keppens C, Palma J, Das P, Scudder S, Wen W, Normanno N . Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn. 2018; 20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006. View

Ulivi P . Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. Int J Mol Sci. 2016; 17(7). PMC: 4964555. DOI: 10.3390/ijms17071186. View

Russo A, Perez D, Gunasekaran M, Scilla K, Lapidus R, Cooper B . Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev Mol Diagn. 2019; 19(12):1099-1108. DOI: 10.1080/14737159.2020.1680287. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Paweletz C, Sacher A, Raymond C, Alden R, OConnell A, Mach S . Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res. 2015; 22(4):915-22. PMC: 4755822. DOI: 10.1158/1078-0432.CCR-15-1627-T. View

10.

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W . Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020; 10(12):1842-1853. PMC: 8358981. DOI: 10.1158/2159-8290.CD-20-0047. View

11.

Darbeheshti F, Yu F, Makrigiorgos G . Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications. Cancers (Basel). 2022; 14(13). PMC: 9264780. DOI: 10.3390/cancers14133143. View

12.

Zill O, Banks K, Fairclough S, Mortimer S, Vowles J, Mokhtari R . The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018; 24(15):3528-3538. DOI: 10.1158/1078-0432.CCR-17-3837. View

13.

Wu Y, Lee V, Liam C, Lu S, Park K, Srimuninnimit V . Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 2018; 126:1-8. DOI: 10.1016/j.lungcan.2018.10.004. View

14.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

15.

Qian X, Liu J, Sun Y, Wang M, Lei H, Luo G . Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget. 2016; 7(20):29154-65. PMC: 5045385. DOI: 10.18632/oncotarget.8684. View

16.

Ferrara M, Di Noia V, DArgento E, Vita E, Damiano P, Cannella A . Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers (Basel). 2020; 12(5). PMC: 7281569. DOI: 10.3390/cancers12051196. View

17.

Farago A, Taylor M, Doebele R, Zhu V, Kummar S, Spira A . Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. JCO Precis Oncol. 2018; 2018. PMC: 6132056. DOI: 10.1200/PO.18.00037. View

18.

Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K . EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 2017; 113:37-44. DOI: 10.1016/j.lungcan.2017.08.021. View

19.

Dagogo-Jack I, Rooney M, Lin J, Nagy R, Yeap B, Hubbeling H . Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity. Clin Cancer Res. 2019; 25(22):6662-6670. PMC: 6858956. DOI: 10.1158/1078-0432.CCR-19-1436. View

20.

Reck M, Hagiwara K, Han B, Tjulandin S, Grohe C, Yokoi T . ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. J Thorac Oncol. 2016; 11(10):1682-9. DOI: 10.1016/j.jtho.2016.05.036. View